These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Protective efficacy of IgM monoclonal antibodies in experimental group B streptococcal infection is a function of antibody avidity. Pincus SH; Shigeoka AO; Moe AA; Ewing LP; Hill HR J Immunol; 1988 Apr; 140(8):2779-85. PubMed ID: 2451694 [TBL] [Abstract][Full Text] [Related]
7. Comparison of functional activities between IgG1 and IgM class-switched human monoclonal antibodies reactive with group B streptococci or Escherichia coli K1. Raff HV; Bradley C; Brady W; Donaldson K; Lipsich L; Maloney G; Shuford W; Walls M; Ward P; Wolff E J Infect Dis; 1991 Feb; 163(2):346-54. PubMed ID: 1988519 [TBL] [Abstract][Full Text] [Related]
8. An IgA monoclonal antibody directed against type III antigen on group B streptococci acts as an opsonin. Bohnsack JF; Hawley MM; Pritchard DG; Egan ML; Shigeoka AO; Yang KD; Hill HR J Immunol; 1989 Nov; 143(10):3338-42. PubMed ID: 2681414 [TBL] [Abstract][Full Text] [Related]
9. Use of hybridoma immunoglobulin switch variants in the analysis of the protective properties of anti-lipopolysaccharide antibodies in Escherichia coli K1 infection. Pelkonen S; Pluschke G Immunology; 1989 Oct; 68(2):260-4. PubMed ID: 2680911 [TBL] [Abstract][Full Text] [Related]
10. Human monoclonal antibody homodimers. Effect of valency on in vitro and in vivo antibacterial activity. Wolff EA; Esselstyn J; Maloney G; Raff HV J Immunol; 1992 Apr; 148(8):2469-74. PubMed ID: 1560202 [TBL] [Abstract][Full Text] [Related]